INSIGHTS INTO MOLECULAR GLUE DEGRADERS: A REVIEW | ||||
| Al-Azhar Journal of Pharmaceutical Sciences | ||||
| Volume 70, Issue 2, September 2024, Page 74-102 PDF (1.66 MB) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/ajps.2024.429454 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Mohamed Ayman ALy El-Zahabi   1; Abdullah El-Nagar2; Hazem Elkady2
| ||||
| 1Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt. | ||||
| 2Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt | ||||
| Abstract | ||||
| Researchers in drug discovery are continually investigating new approaches to develop potential anticancer agents that are effective, safe, tolerable, and exhibit reduced resistance. Targeted protein degraders (TPD) represent a progressive paradigm in drug discovery. Conventional small molecules are generally designed to inhibit specific targets, whereas molecular glues function to recruit critical problematic proteins to the ubiquitin-proteasome system (UPS), resulting in the degradation of disease-causing proteins through proteolysis. This study highlights the critical functions of TPD, particularly molecular glue degraders, in combating cancer and their implications for anticancer strategies. We aim to summarize recent advancements and offer insights into the development of medications associated with TPD technologies. | ||||
| Keywords | ||||
| anti-tumor; targeted protein degraders; molecular glues; molecular prosthetics; PROTACs; HyTs | ||||
|
Supplementary Files
|
||||
|
Statistics Article View: 190 PDF Download: 209 |
||||
